Overview

Effect of P-glycoprotein Inhibition on Lenalidomide Pharmacokinetics in Healthy Males

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
To find out if the blood level of lenalidomide can be changed when a drug that prevents p-glycoprotein (a protein naturally present in the body that helps carry substances across cell membranes that is found in many parts of the body like the intestines, liver, and kidneys) from working (called a P-gp inhibitor) when taken together with lenalidomide. The study is also trying to find out if blood level of temsirolimus can be changed when a subject takes lenalidomide together with temsirolimus.
Phase:
Phase 1
Details
Lead Sponsor:
Celgene
Celgene Corporation
Collaborator:
Covance
Treatments:
Diphenhydramine
Everolimus
Krestin
Lenalidomide
Promethazine
Quinidine
Quinidine gluconate
Sirolimus
Thalidomide